-

Mindpeak's AI Comes out on Top in Comparative Study on HER2-low Scoring by Cypath and Institut Gustave Roussy

HAMBURG, Germany--(BUSINESS WIRE)--In a first of its kind comparative study, Mindpeak's CE-marked HER2 AI for breast cancer diagnosis was compared to three other commercial AIs (e.g. Visiopharm). Mindpeak's AI showed the highest accuracy of all AIs in terms of balanced clinical scores (88.1%) for HER2-low, higher than the score of the next best AI (67.3%) and higher than the concordance of pathologists with the reference score (85.5%). Furthermore, Mindpeak's AI received the highest scores in a usability evaluation of the AI softwares in all categories. This study was conducted by Cypath-RB together with Institut Gustave Roussy and was presented at the world's leading annual meeting for pathology, the USCAP 2023 (United States and Canadian Academy of Pathology), in New Orleans in mid-March. 197 tissue samples from breast cancer patients were examined. The study was sponsored by AstraZeneca. Vidal T et al. (2023) USCAP poster board #24, abstract ID 984

Breast cancer is the most common cancer in women and accounts for about one third of all malignancies in women. Breast cancer forms metastases at an increased rate and has so far resulted in a high mortality rate. Early detection of this disease leads to improved treatment outcomes and significantly higher survival rates. The use of molecular biomarkers ensures that breast cancer patients receive more and more targeted treatment. Biomarkers such as HER2 play a central role in predicting prognosis and determining individual therapy. More than half of metastasized breast cancers express low levels of HER2, traditionally associated with poor outcome. Recent clinical studies have shown the efficacy treatment (Enhertu, AstraZeneca) in this patient group with significant clinical benefit compared to standard-of-care treatment.

About Mindpeak

Mindpeak is Europe's leading provider of AI software for pathology. Over 10,000 patients have been diagnosed with the help of Mindpeak's AI. With a focus on tissue biomarker analysis and discovery, Mindpeak serves clinical laboratories and biopharma companies around the world. Mindpeak's AI-algorithms were the first to be used in routine clinical diagnostics in the US and EU.

https://is.gd/9Zfx63

Contacts

Press contact:
Carsten Maltzan
carsten.maltzan@mindpeak.ai

Mindpeak


Release Versions

Contacts

Press contact:
Carsten Maltzan
carsten.maltzan@mindpeak.ai

Social Media Profiles
More News From Mindpeak

Mindpeak to deploy and evaluate AI-Powered Digital Pathology Risk Assessment Tools for Breast Cancer in collaboration with AstraZeneca

HAMBURG, Germany--(BUSINESS WIRE)--The collaboration aims to assess the transformative potential of AI in digital pathology, with a specific focus on accelerating primary breast cancer diagnosis. Breast cancer remains one of the leading causes of cancer-related deaths in women worldwide. Early and accurate diagnosis is essential for significantly improving clinical outcomes and patient survival rates. However, this process is often hindered by a limited pathology workforce and time-consuming ca...

ZEISS and Mindpeak partner to advance Multiplex Immunofluorescence (mIF) solutions for pathology

HAMBURG, Germany--(BUSINESS WIRE)--ZEISS partners with Mindpeak, a pioneer in AI-powered pathology solutions, to develop an integrated Multiplex Immunofluorescence (mIF) solution that serves pathologists across research, diagnostics, and clinical applications. Mindpeak’s expertise in AI-based image analysis of pathological tissues, particularly through its established algorithms for clinical routine applications, complements ZEISS's advanced instruments and software for research applications of...

Mindpeak and Sagis Diagnostics to launch Collaborative Study on AI-Enhanced Detection of Nail Mycosis

HAMBURG, Germany & HOUSTON--(BUSINESS WIRE)--Mindpeak, GmbH, the leader in AI-powered pathological solutions, today announced the collaboration with Sagis DX to conduct a spearheading study, assessing the efficacy of the new Mindpeak Onychomycosis AI algorithm. This innovative technology has potential to revolutionize the detection of onychomycosis on PAS-stained whole slide images, showcasing the transformative power of AI in the field of pathology. The Mindpeak Onychomycosis AI algorithm is d...
Back to Newsroom